Analysts Offer Predictions for TSE:MDP FY2025 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities researchers at Leede Financial decreased their FY2025 earnings estimates for Medexus Pharmaceuticals in a report released on Monday, February 24th. Leede Financial analyst D. Loe now expects that the company will earn $0.21 per share for the year, down from their prior forecast of $0.29. Leede Financial currently has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2026 earnings at $0.21 EPS, FY2027 earnings at $0.54 EPS and FY2028 earnings at $0.94 EPS.

MDP has been the subject of a number of other research reports. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Stifel Nicolaus cut Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the company from C$6.00 to C$3.45 in a report on Friday, February 7th. Stifel Canada downgraded Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Finally, Raymond James upgraded Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a report on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Medexus Pharmaceuticals has a consensus rating of “Buy” and an average target price of C$5.49.

Medexus Pharmaceuticals Price Performance

MDP stock opened at C$2.88 on Wednesday. Medexus Pharmaceuticals has a 1 year low of C$1.47 and a 1 year high of C$5.56. The firm has a market capitalization of C$64.48 million, a PE ratio of 13.77 and a beta of 1.96. The business has a 50 day simple moving average of C$3.58 and a 200-day simple moving average of C$2.90.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.